Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk acute myeloid leukemia (AML) and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) maintenance post-hematopoietic cell transplant (HCT) Meeting Abstract

  

Authors:	DiPersio, J.; Cooper, B. W.; Suh, H. C.; Koura, D.; Bernard, L.; Shah, N. N.; Walter, R. B.; Perales, M. A.; Mapara, M.; Tamari, R.; Loken, M. R.; Breitschwerdt, K.; Nath, S.; Raffel, G. D.; Koehne, G.
Abstract Title:	Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk acute myeloid leukemia (AML) and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) maintenance post-hematopoietic cell transplant (HCT)
Meeting Title:	65th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	142
Issue:	Suppl. 1
Meeting Dates:	2023 Dec 9-12
Meeting Location:	San Deigo, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2023-11-02
Start Page:	483
Language:	English
ACCESSION:	WOS:001159306701240
DOI:	10.1182/blood-2023-190037
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/214401